Guerbet SA is a French pharmaceutical group specializing in the research, development, production, and sale of contrast media for medical imaging. Founded in 1926 by André Guerbet, the company traces its roots to the discovery of Lipiodol, the first iodinated X-ray contrast agent in 1901. It offers a comprehensive portfolio of products for X-ray imaging (approximately 57% of sales), MRI (31%), and other modalities like ultrasound and nuclear medicine, including brands such as Dotarem, Xenetix, Optiray, and the FDA-approved Elucirem (Gadopiclenol) for MRI. Guerbet operates eight production sites across France, the United States, Ireland, and Brazil, employing around 2,800 people worldwide. With a global presence, Europe represents about 37% of net sales, while the company serves healthcare professionals in diagnostic and interventional radiology. Recognized as a key player in the growing contrast media market, Guerbet maintains full control over its supply chain, supporting advancements in medical imaging technologies and procedures.